Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
120
-
Total 13F shares, excl. options
-
57.3M
-
Shares change
-
+2.81M
-
Total reported value, excl. options
-
$736M
-
Value change
-
+$35.3M
-
Put/Call ratio
-
0.76
-
Number of buys
-
76
-
Number of sells
-
-49
-
Price
-
$12.83
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2018
142 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q4 2018.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57.3M shares
of 114M outstanding shares and own 50.16% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (10.4M shares), FMR LLC (7.38M shares), BlackRock Inc. (5.03M shares), FRANKLIN RESOURCES INC (3.24M shares), Casdin Capital, LLC (2.55M shares), Vanguard Group Inc (2.54M shares), FARALLON CAPITAL MANAGEMENT LLC (2.2M shares), Artal Group S.A. (2.15M shares), STATE STREET CORP (2.03M shares), and Polaris Venture Management Co. V, L.L.C. (1.82M shares).
This table shows the top 120 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.